The Study Of Hemorheological Character And Drug Effect In The Patients With Different Kinds Of Cerebral Infarct

Object: To approach the difference of pathogenic mechanism in the patients with different kinds of cerebral infarct and to appreciate the pharmacal mechanism, clinical efficacy and security of Batroxobin.Methods: Hemorheological parameters were measured in 124 patients with cerebral infarct. All patients were divided into the two groups according to head CT or MIR. One was major blood vessels or cortical branch occlusion group, the other was central branch occlusion group.The hemorheological change of the great cerebral infarct was compared with that of lunar infarct. All patients with acute cerebral infarct were divided into therapy group and control group. The control group, xue setong was administrated once a day. The therapy group, Batroxobin 10BU, 5BU ,5BU were adminiatated at 1,3,5 days after diagnosis. The patients with hypertension or diabetes were treated accordingly. Hemorheological parameters, plaque count, PT, TT, APTT were measured before and after therapy on day 7. Chinese Stroke Scale (CSS) was assessed before and after therapy on days 1,7,30.Result: Blood viscosity, plasma viscosity, HCT, erythrocyte aggregability and plasma fibrinogen levels was significantly lower in the major blood vessels occlusion group than the central branch occlusion group before therapy (P<0.05 or P<0.01). However, plaque aggregability in the latter was higher than in the former (P<0.01). All hemorheological parameters were significantly lower aftertherapy than before therapy in the therapy group(P<0.05 or P<0.01). Blood viscosity, plasma viscosity, HCT, erythrocyte aggregability and plasma fibrinogen levels were significantly lower after therapy than before therapy in major blood vessels occlusion group(P<0.05 or P<0.01). Blood viscosity, plasma viscosity, HCT,plaque aggregability were significantly lower after therapy than before therapy in the central branch occlusion group(P<0.05 or P<0.01). The therapy group was better than the control about the extent of functional or neurological improvement on the 7-day and one month after therapy (P<0.01). With regard to plaque count, PT, TT, APTT, no differences were seen in the therapy group and the control before and after therapy.Conclusion: With regard to pathogenic mechanism, the difference was found between the major blood vessels occlusion and the central branch occlusion. The therapy efficacy of Batroxobin was certain. It was safe that patients with cerebral infarcts were treated with Batroxobin.